1. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM. Tests of glycemia in diabetes. Diabetes Care 1995;18:896–909. PMID:
7555528.
3. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO Consultation. Geneva: World Health Organization. 2011.
4. Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med 2014;29:388–394. PMID:
24002631.
5. Parrinello CM, Selvin E. Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management. Curr Diab Rep 2014;14:548. PMID:
25249070.
6. National Glycohemoglobin Standardization Program (NGSP). Factors that Interfere with HbA1c test results [Internet]. NGSP. c2011;cited 2015 May 20. Available from:
http://www.ngsp.org/factors.asp.
7. Polgreen PM, Putz D, Stapleton JT. Inaccurate glycosylated hemoglobin A1C measurements in human immunodeficiency virus-positive patients with diabetes mellitus. Clin Infect Dis 2003;37:e53–e56. PMID:
12905153.
8. Brown JN, Kemp DW, Brice KR. Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis. Pharmacotherapy 2009;29:468–472. PMID:
19323622.
9. Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis 2004;44:715–719. PMID:
15384023.
10. Suzuki S, Koga M, Niizeki N, Furuya A, Matsuo K, Tanahashi Y, et al. Evaluation of glycated hemoglobin and fetal hemoglobin-adjusted HbA1c measurements in infants. Pediatr Diabetes 2013;14:267–272. PMID:
23350671.
11. Suzuki S, Koga M, Amamiya S, Nakao A, Wada K, Okuhara K, et al. Glycated albumin but not HbA1c reflects glycaemic control in patients with neonatal diabetes mellitus. Diabetologia 2011;54:2247–2253. PMID:
21644010.
13. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. Osaka IDDM Study Group. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 2000;342:301–307. PMID:
10655528.
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986. PMID:
8366922.
15. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993;341:1306–1309. PMID:
8098449.
16. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304–309. PMID:
8147960.
17. Mosca A, Carenini A, Zoppi F, Carpinelli A, Banfi G, Ceriotti F, et al. Plasma protein glycation as measured by fructosamine assay. Clin Chem 1987;33:1141–1146. PMID:
3594841.
18. Pandya HC, Livingstone S, Colgan ME, Percy-Robb IW, Frier BM. Serum fructosamine as an index of glycaemia: comparison with glycated haemoglobin in diabetic and non-diabetic individuals. Pract Diabetes Int 1987;4:126–128.
19. Narbonne H, Renacco E, Pradel V, Portugal H, Vialettes B. Can fructosamine be a surrogate for HbA(1c) in evaluating the achievement of therapeutic goals in diabetes? Diabetes Metab 2001;27(5 Pt 1):598–603. PMID:
11694860.
20. Matsumoto H, Murase-Mishiba Y, Yamamoto N, Sugitatsu-Nakatsukasa S, Shibasaki S, Sano H, et al. Glycated albumin to glycated hemoglobin ratio is a sensitive indicator of blood glucose variability in patients with fulminant type 1 diabetes. Intern Med 2012;51:1315–1321. PMID:
22687835.
21. Howey JE, Browning MC, Fraser CG. Assay of serum fructosamine that minimizes standardization and matrix problems: use to assess components of biological variation. Clin Chem 1987;33(2 Pt 1):269–272. PMID:
3802511.
22. Miyazaki A, Kohzuma T, Kasayama S, Koga M. Classification of variant forms of haemoglobin according to the ratio of glycated haemoglobin to glycated albumin. Ann Clin Biochem 2012;49(Pt 5):441–444. PMID:
22715294.
23. Kim D, Kim KJ, Huh JH, Lee BW, Kang ES, Cha BS, et al. The ratio of glycated albumin to glycated haemoglobin correlates with insulin secretory function. Clin Endocrinol (Oxf) 2012;77:679–683. PMID:
22150917.
24. Koga M, Hashimoto K, Murai J, Saito H, Mukai M, Ikegame K, et al. Usefulness of glycated albumin as an indicator of glycemic control status in patients with hemolytic anemia. Clin Chim Acta 2011;412:253–257. PMID:
20965159.
25. Juraschek SP, Steffes MW, Selvin E. Associations of alternative markers of glycemia with hemoglobin A(1c) and fasting glucose. Clin Chem 2012;58:1648–1655. PMID:
23019309.
26. Lee JW, Kim HJ, Kwon YS, Jun YH, Kim SK, Choi JW, et al. Serum glycated albumin as a new glycemic marker in pediatric diabetes. Ann Pediatr Endocrinol Metab 2013;18:208–213. PMID:
24904879.
27. Shin YS, Park J, Kang DS, Yu J. Significance of the measurement of serum fructosamine in the management of childhood diabetes. Int J Pediatr Endocrinol 2013;2013(Suppl 1):P36.
28. Koga M, Murai J, Morita S, Saito H, Kasayama S. Comparison of annual variability in HbA1c and glycated albumin in patients with type 1 vs. type 2 diabetes mellitus. J Diabetes Complications 2013;27:211–213. PMID:
23312788.
29. Hirsch IB, Brownlee M. Beyond hemoglobin A1c--need for additional markers of risk for diabetic microvascular complications. JAMA 2010;303:2291–2292. PMID:
20530784.
30. Chon S, Lee YJ, Fraterrigo G, Pozzilli P, Choi MC, Kwon MK, et al. Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus. Diabetes Technol Ther 2013;15:455–460. PMID:
23617251.
31. Koga M, Murai J, Saito H, Otsuki M, Kasayama S. Evaluation of the glycated albumin/HbA1c ratio by stage of diabetic nephropathy. Diabetol Int 2011;2:141–145.
32. Koga M, Murai J, Saito H, Matsumoto S, Kasayama S. Effects of thyroid hormone on serum glycated albumin levels: study on non-diabetic subjects. Diabetes Res Clin Pract 2009;84:163–167. PMID:
19243849.
33. Suzuki S, Koga M, Takahashi H, Matsuo K, Tanahashi Y, Azuma H. Glycated albumin in patients with neonatal diabetes mellitus is apparently low in relation to glycemia compared with that in patients with type 1 diabetes mellitus. Horm Res Paediatr 2012;77:273–276. PMID:
22538993.
34. Koga M. Glycated albumin: clinical usefulness. Clin Chim Acta 2014;433:96–104. PMID:
24631132.
35. Koga M, Matsumoto S, Saito H, Kasayama S. Body mass index negatively influences glycated albumin, but not glycated hemoglobin, in diabetic patients. Endocr J 2006;53:387–391. PMID:
16717395.
36. Suzuki S, Koga M, Niizeki N, Furuya A, Takahashi H, Matsuo K, et al. Glycated albumin is lower in infants than in adults and correlated with both age and serum albumin. Pediatr Diabetes 2013;14:25–30. PMID:
22816963.
37. Yamanouchi T, Akanuma Y. Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res Clin Pract 1994;24(Suppl):S261–S268. PMID:
7859616.
38. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. Diabetes Technol Ther 2003;5:355–363. PMID:
12828817.
39. Dungan KM. 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 2008;8:9–19. PMID:
18088226.
40. Yamanouchi T, Minoda S, Yabuuchi M, Akanuma Y, Akanuma H, Miyashita H, et al. Plasma 1,5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes 1989;38:723–729. PMID:
2656341.
41. Stettler C, Stahl M, Allemann S, Diem P, Schmidlin K, Zwahlen M, et al. Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care 2008;31:1534–1535. PMID:
18426859.
42. Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawamori R, et al. 1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 1995;18:1156–1159. PMID:
7587851.
43. McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T, et al. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 2004;27:1859–1865. PMID:
15277408.
44. Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006;29:1214–1219. PMID:
16731998.
45. Seok H, Huh JH, Kim HM, Lee BW, Kang ES, Lee HC, et al. 1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes. Diabetes Metab J 2015;39:164–170. PMID:
25922811.
46. Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014;37:2034–2054. PMID:
24935775.
47. Juraschek SP, Steffes MW, Miller ER 3rd, Selvin E. Alternative markers of hyperglycemia and risk of diabetes. Diabetes Care 2012;35:2265–2270. PMID:
22875225.
48. Rondeau P, Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie 2011;93:645–658. PMID:
21167901.
49. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, et al. Tests of glycemia in diabetes. Diabetes Care 2004;27:1761–1773. PMID:
15220264.